GTS-21 2HCl - CAS# 156223-05-1 092 Currently GSK2879552 is in phase

Currently GSK2879552 is in phase I clinical trials targeting Acute Myeloid Leukemia (AML) and Relapsed/Refractory Small Cell Lung Carcinoma

Activation of human FFA4 by TUG-891 also results in rapid phosphorylation and internalization of the receptor

InChiKey: LQBVNQSMGBZMKD-UHFFFAOYSA-N

such as BMP4

1030846-42-4

GTS-21 2HCl - CAS# 156223-05-1 092 Currently GSK2879552 is in phaseGTS 21 2HCl, also known as DMBX A, CAS No. 156223 05 1, is a derivative of the natural product anabaseine that acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds to both the 42 and 7 subtypes, but activates only the 7 to any significant extent. Both GTS 21 itself and its demethylated active metabolite 4 OH GTS 21 display nootropic and neuroprotective effects, and GTS 21 is being investigated for the treatment of